Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

EVOaware An evolution-focused platform for cancer drug discovery

Coordinator
Fundacio Institut De Bioenginyeria De Catalunya, Spain
Runs
1 December 2025 to 31 May 2027
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101248631

What the project is doing

In the project's own words, from its summary on CORDIS.

Solid tumours frequently develop resistance to therapies, leading to treatment failure. This resistance arises from the complex interplay between heterogeneous cancer cell populations and their microenvironment, driving tumour evolution and local adaptation. Current drug discovery pipelines fall short in addressing this complexity. In this ERC-PoC, we will develop EVOaware, a groundbreaking platform that integrates genome editing, spatial barcoding, high-throughput drug screening, multimodal spatial omics, and spatial pattern analysis, to address the critical challenge of therapeutic resistance in cancer from the lens of evolution.

Ultimately, EVOaware will accelerate the discovery and development of novel cancer therapies, leading to improved patient outcomes.

Topics

Who is involved

OrganisationCityCountryRole
Fundacio Institut De Bioenginyeria De CatalunyaBarcelonaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI